Cold Genesys secures $22M Series C round for oncolytic virus in bladder cancer
The company's lead product candidate, CG0070, has completed a Phase II study and will be tested in another trial, combined with Merck's Keytruda.
The company's lead product candidate, CG0070, has completed a Phase II study and will be tested in another trial, combined with Merck's Keytruda.
Cold Genesys, a sort of latter-day spinoff of the once-promising cancer vaccine maker Cell Genesys, has an engineered oncolytic virus that shows promise in treating a dangerous form of bladder cancer. The Newport Beach, California company just received $13.6 million from Hong Kong-based investment fund Ally Bridge Group. It has rejiggered an adenovirus that typically causes […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.